EUVIMEDEUVIMED entdecken
Open Access

Evaluation of the Cepheid 3-gene host response blood test for tuberculosis diagnosis and treatment response monitoring in a primary-level clinic in rural China

Meng Li iD, Yong Qiu, Mingcheng Guo, Rong Qu, Fajun Tian, Gengsheng Wang, Ya Wang, Jian Ma, Siyuan Liu, Howard Takiff iD, Yi-Wei Tang iD, Qian Gao iD

Journal of Clinical Microbiology · 21.11.2023 · 61 (11)

DOI: 10.1128/jcm.00911-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Microbiology, erschienen am 21.11.2023. Verfasst von Meng Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Shanghai Medical College, Shanghai Institute of Infecti…. Hauptthemen laut MEDLINE: Tuberculosis, Pulmonary, Antibiotics, Antitubercular, Tuberculosis, Mycobacterium tuberculosis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Shanghai Municipal Science and Technology Major Project, MOST | National Natural Science Foundation of China (NSFC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A rapid, accurate, non-sputum-based triage test for diagnosing tuberculosis (TB) is a high-priority need. Cepheid developed a novel prototype blood test, Xpert Mycobacterium tuberculosis Host Response (Xpert-MTB-HR), which generates a TB score based on the mRNA expression of three genes. We conducted a case-control study with prospective recruitment to evaluate its accuracy in the clinic of the Wusheng County Centers for Disease Prevention and Control in China. We enrolled 149 TB patients, 248 other respiratory diseases (ORD) patients, and 193 healthy controls. In addition, whole-blood samples taken from TB patients after 2, 5, and 6 months of treatment were tested with Xpert-MTB-HR to evaluate its ability to monitor treatment response. Xpert-MTB-HR discriminated between TB and healthy controls with an area under the curve (AUC) of 0.912 (95% CI, 0.878–0.945). With the specificity of 70% envisioned for a triage test, its sensitivity was 90.1% (84.9%–94.6%). Xpert-MTB-HR discriminated between TB and ORD with an AUC of 0.798 (0.750–0.847), and at specificity of 70%, the sensitivity was only 75.8% (68.5%–82.8%). In patients determined by Ultra to have medium or high sputum bacillary loads, with specificity of 70%, the sensitivity for discriminating patients with TB from healthy controls was 100.0% (100.0–100.0) and from patients with ORD, 95.1% (89.8–100.0). The TB scores generally increased by 2 months of treatment and then remained stable. Xpert-MTB-HR met the criteria for a triage test to discriminate between TB and healthy controls, but not between TB and ORD, except when limited to patients with high sputum bacillary loads. Xpert-MTB-HR showed promise for monitoring response to treatment but needs to be further evaluated in larger prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, PulmonaryAntibiotics, AntitubercularTuberculosisMycobacterium tuberculosisHumansProspective StudiesRifampinCase-Control StudiesSensitivity and SpecificitySputumChina

Stichwörter der Autor:innen

3-gene signatureCepheiddiagnosticshost responsenon-sputumtuberculosis

Substanzen

RifampinAntibiotics, Antitubercular

Autor:innen und Institutionen

  • Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Shanghai Medical College, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University , Shanghai, China.
  • Wusheng County Center for Disease Control and Prevention , Guang'an, China.
  • Medical Affairs, Danaher Diagnostic Platform/Cepheid , Shanghai, China.
  • Laboratorio de Genética Molecular, CMBC, Instituto Venezolano de Investigaciones Científicas, IVIC , Caracas, Venezuela.

ORCID-Profile: Meng Li, Howard Takiff, Yi-Wei Tang, Qian Gao

Förderung

  • Shanghai Municipal Science and Technology Major Project
  • MOST | National Natural Science Foundation of China (NSFC)

Zitieren

APA

Li, M., Qiu, Y., Guo, M., Qu, R., Tian, F., Wang, G., Wang, Y., Ma, J., Liu, S., Takiff, H., Tang, Y. W., & Gao, Q. (2023). Evaluation of the Cepheid 3-gene host response blood test for tuberculosis diagnosis and treatment response monitoring in a primary-level clinic in rural China. Journal of Clinical Microbiology, 61(11). https://doi.org/10.1128/jcm.00911-23

Vancouver

Li M, Qiu Y, Guo M, Qu R, Tian F, Wang G, et al. Evaluation of the Cepheid 3-gene host response blood test for tuberculosis diagnosis and treatment response monitoring in a primary-level clinic in rural China. Journal of Clinical Microbiology. 2023;61(11). doi:10.1128/jcm.00911-23

BibTeX
@article{Li2023,
  author = {Li, Meng and Qiu, Yong and Guo, Mingcheng and Qu, Rong and Tian, Fajun and Wang, Gengsheng and Wang, Ya and Ma, Jian and Liu, Siyuan and Takiff, Howard and Tang, Yi-Wei and Gao, Qian},
  title = {Evaluation of the Cepheid 3-gene host response blood test for tuberculosis diagnosis and treatment response monitoring in a primary-level clinic in rural China},
  journal = {Journal of Clinical Microbiology},
  year = {2023},
  volume = {61},
  number = {11},
  doi = {10.1128/jcm.00911-23}
}
Kostenlos starten →